REGENERX BIOPHARMACEUTICALS
RGN
RGN was delisted on the 22nd of December, 2010.
2 hedge funds and large institutions have $36K invested in REGENERX BIOPHARMACEUTICALS in 2017 Q4 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 2 → 2 (0)
43% less capital invested
Capital invested by funds: $63K → $36K (-$27K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DBIA
Dumont & Blake Investment Advisors
Princeton,
New Jersey
|
+$3.3K |
Top Sellers
RGN Hedge Fund Activity: Q4 2017 in Review
2 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in REGENERX BIOPHARMACEUTICALS (RGN) for Q4 2017, worth a combined $36K — down 43% from $63K a quarter earlier.
Fund positioning in RGN was balanced in Q4 2017: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was Dumont & Blake Investment Advisors, adding an estimated $3.3K.
- 2 institutional investors held REGENERX BIOPHARMACEUTICALS (RGN) as of Q4 2017, unchanged from Q3 2017.
- Funds reported $36K of REGENERX BIOPHARMACEUTICALS stock for Q4 2017, down 43% quarter-over-quarter.
- 0 funds opened new REGENERX BIOPHARMACEUTICALS positions in Q4 2017 and 0 closed out.
- The largest REGENERX BIOPHARMACEUTICALS buyer in Q4 2017 was Dumont & Blake Investment Advisors, an estimated $3.3K added.
Based on aggregated 13F filings for Q4 2017.